Equity Overview
Price & Market Data
Price: $1.53
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $40,247,108
Daily Volume: 0
Performance Metrics
1 Week: 0.66%
1 Month: 12.50%
3 Months: 22.11%
6 Months: 63.46%
1 Year: -15.00%
YTD: 60.88%
Company Details
Employees: 34
Sector: Health technology
Industry: Biotechnology
Country:
Details
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.